Pharmaxis Of Australia Experiences EU Setback For CF Drug
This article was originally published in PharmAsia News
Executive Summary
Australia's Pharmaxis saw huge stock market losses after the European Union indicated it would deny approval of Bronchitol for treating cystic fibrosis
|
Australia's Pharmaxis saw huge stock market losses after the European Union indicated it would deny approval of Bronchitol for treating cystic fibrosis. The fear of analysts following Pharmaxis stock decline is that eventual EU rejection of the drug could be duplicated in the United States where Bronchitol is under review. The EU decision is subject to final approval, a decision analysts see as key to the fortunes of Pharmaxis. (Click here for more) "Brave Profit On Pharmaxis Misfortune" - Australian (5/30/11) |